April 28, 2020 / 9:28 PM / a month ago

BRIEF-Erytech Provides Update On The Trybeca-1 Phase 3 Clinical Trial Of Eryaspase In Second Line Pancreatic Cancer

April 28 (Reuters) - Erytech Pharma SA:

* ERYTECH PROVIDES UPDATE ON THE TRYBECA-1 PHASE 3 CLINICAL TRIAL OF ERYASPASE IN SECOND LINE PANCREATIC CANCER

* ERYTECH PROVIDES UPDATE ON THE TRYBECA-1 PHASE 3 CLINICAL TRIAL OF ERYASPASE IN SECOND LINE PANCREATIC CANCER

* ERYTECH PHARMA SA - TRIAL TO CONTINUE AS PLANNED AFTER THIRD SAFETY REVIEW BY INDEPENDENT DATA MONITORING COMMITTEE

* ERYTECH PHARMA SA - INTERIM SUPERIORITY ANALYSIS EXPECTED AROUND YEAR-END; FINAL ANALYSIS IN SECOND HALF OF 2021

* ERYTECH PHARMA SA - NO SAFETY ISSUES WERE IDENTIFIED AND IDMC RECOMMENDED TO CONTINUE TRIAL AS PLANNED

* ERYTECH PHARMA SA - TO DATE, MORE THAN 75% OF APPROXIMATELY 500 PATIENTS TO BE ENROLLED IN TRIAL HAVE BEEN RANDOMIZED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below